A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
Sponsor: Omnix Medical Ltd
Listed as NCT06087536, this PHASE2 trial focuses on Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia and remains actively recruiting participants. Sponsored by Omnix Medical Ltd, it has been updated 9 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Recruiting PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Omnix Medical Ltd
For direct contact, visit the study record on ClinicalTrials.gov .